Introduction {#Sec1}
============

As the most severe type of coronary artery diseases, myocardial infarction (MI) has posed a threat to public health because of its high morbidity and mortality. More than 600,000 people suffer from MI, which leads to 180,000 deaths yearly in China \[[@CR1], [@CR2]\]. In recent years, the incidence of premature myocardial infarction (PMI) has gradually increased \[[@CR3]\]. It has been shown that genetics plays a central role in the development of PMI, with its heritability estimated at approximately 63% \[[@CR4]\]. It was also reported that about 10--15% of PMI cases were caused by essential mutations in genes related to cholesterol metabolism \[[@CR5]\]. Familial hypercholesterolemia (FH) is one of the most common genetic disorders of cholesterol metabolism \[[@CR6]\], and the mutations in FH-associated genes, such as low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), proprotein convertase subtilisin/kexin type 9 (PCSK9) and low-density lipoprotein receptor adaptor protein 1 (LDLRAP1), can increase the plasma levels of low-density lipoprotein cholesterol (LDL-C) and lead to PMI.

A previous study carried out by the author of this study showed that the prevalence of FH diagnosed by genetic testing was 4.4% \[[@CR7]\]. However, it was also found that not all clinical phenotypes of PMI matched gene mutations. Therefore, this article aimed to investigate the relationship between FH-associated gene and the phenotype of PMI to clarify the genetic spectrum of PMI.

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

All MI patients were enrolled at Peking University People's Hospital between May 1, 2015 and March 31, 2017. MI, including ST-segment elevation MI and non-ST-segment elevation MI, which was defined according to the Third Universal Definition of Myocardial Infarction \[[@CR8]\]. PMI patients (age at the first MI onset: males of ≤55 years old, or females of ≤60 years old) were included as the experimental group, while gender matched patients free of PMI (non-PMI, age at the first MI onset: males of ≤55 years old, or females of ≤60 years old) were enrolled as the control group. PMI patients with incomplete clinical data or with no blood samples were excluded. The investigational protocol of this study was approved by the ethics review board of Peking University People's Hospital and was registered into the Chinese Clinical Trial Register (registration number: ChiCTR-OCH-12002349, registry URL: <http://www.chictr.org.cn/showproj.aspx?proj=7201>). All subjects provided written informed consent at the time of their enrollment. The investigational protocol was designed in accordance with CONSORT2010.

Collection of clinical and laboratory data {#Sec4}
------------------------------------------

Data of PMI patients were retrieved from previously published studies to assess the clinical characteristics of PMI \[[@CR7]\]. The clinical characteristics of non-PMI patients, including age, sex, body mass index (BMI), and family history of premature coronary heart disease (CHD), were collected via their medical records. Laboratory examination results, such as those of routine blood test and biochemical test carried out during the first 24 h after hospital admission, were also obtained. The severity of CHD was assessed according to the Gensini score system described in a previous study \[[@CR9]\]. A family history of premature CHD was defined as males of \< 55 years old or females of \< 60 years old in the first-degree relatives.

Diagnostic criteria for FH {#Sec5}
--------------------------

FH was diagnosed using "2018 Chinese expert consensus of FH screening and diagnosis" \[[@CR10]\]. Adults who met 2 of the following criteria could be diagnosed as FH: (1) untreated LDL-C ≥ 4.7 mmol/L (180 mg/dl); (2) skin/tendon xanthoma or corneal arcus in a person of \< 45 years old; (3) A first-degree relative with FH or premature arteriosclerotic cardiovascular disease (ASCVD). In addition, FH was also diagnosed by detecting the pathogenic mutations in LDLR, APOB, PCSK9 and LDLRAP1 genes.

Collection of blood cell samples {#Sec6}
--------------------------------

Peripheral venous blood samples were collected after patients were admitted into the hospital and were processed within 30 min of collection. Blood cells was isolated by centrifugation at 3000 rpm/min for 10 min and then transferred into new tubes, which were stored at − 80 °C until use.

DNA extraction {#Sec7}
--------------

Genomic DNA was extracted from blood cell samples using a DNeasy Blood Kit (Tianyihuyuan, Beijing, China) according to the manufacturer's protocol.

Sequencing and analysis of mutations {#Sec8}
------------------------------------

The entire exon region of LDLR, PCSK9, and LDLRAP1 genes, as well as the exon 26 of APOB gene (from 100 bp to 200 bp of p.Arg3500) located at the LDL receptor-binding site, were studied by Sanger sequencing using an ABI 3730-XL Genetic Analyzer (ABI, Foster City, CA).

The LOVD database ([*https://databases.lovd.nl/shared/genes/*](https://databases.lovd.nl/shared/genes/)), the NCBI-ClinVar database ([*https://www.ncbi.nlm.nih.gov/clinvar/*](https://www.ncbi.nlm.nih.gov/clinvar/)), and the NCBI-Pubmed database ([*https://www.ncbi.nlm.nih.gov/pubmed*](https://www.ncbi.nlm.nih.gov/pubmed)) were used to determine whether the sequenced mutations were "pathogenic" or "potentially pathogenic" mutations that have been reported. Polyphen-2 software was used to predict whether a newly found mutation was pathogenic.

Statistical analysis {#Sec9}
--------------------

SPSS19.0 software was used for analysis. Measurement data with a normal distribution were represented by X ± S and examined using independent samples t-test. Count data were expressed by (RQ) and examined using X^2^ tests. A logistic regression analysis model was used to evaluate the correlation between various risk factors and PMI. *P* \< 0.05 indicated significant difference.

Results {#Sec10}
=======

Genetic phenotypes of PMI patients {#Sec11}
----------------------------------

A total of 225 PMI patients meeting the inclusion criteria were collected, including 188 males (83.6%) and 37 females (16.4%). 19 non-synonymous variants were identified in these PMI patients, including 12 pathogenic mutations and 7 benign variants (Table [1](#Tab1){ref-type="table"}). Among these variants, 5 pathogenic variants (LDLR c.129G \> C, c.1867A \> T; PCSK9 c.1792G \> A; LDLRAP1 c.65G \> C, c.274G \> A) and 4 benign variants (LDLR c.928A \> T, c.2320G \> A; PCSK9 c.517C \> T, c.1954A \> G) were discovered for the first time.Table 1Genetic phenotypes of PMI patientsGeneFunctioncDNA positionProtein positionSignificanceLDLRMissensec.129G \> Cp.Lys43Asnlikely pathogenicPutativeLDLRMissensec.241C \> Tp.Arg81CyspathogenicKnownLDLRMissensec.292G \> Ap.Gly98SerpathogenicKnownLDLRMissensec.1525A \> Gp.Lys509GlupathogenicKnownLDLRMissensec.1691A \> Gp.Asn564SerpathogenicKnownLDLRMissensec.1691A \> Gp.Asn564SerpathogenicKnownLDLRMissensec.1867A \> Tp.Ile623Phelikely pathogenicPutativeLDLRMissensec.2054C \> Tp.Pro685LeupathogenicKnownLDLRMissensec.2054C \> Tp.Pro685LeupathogenicKnownLDLRc.928A \> Tp.Ile310PhebenignPutativeLDLRc.1057G \> Ap.Glu353LysbenignKnownLDLRc.1171G \> Ap.Ala391ThrbenignKnownLDLRc.1516G \> Ap.Val306MetbenignKnownLDLRc.2320G \> Ap.Asp774AsnbenignPutativePCSK9Missensec.277C \> Tp.Arg93CyspathogenicKnownPCSK9Missensec.277C \> Tp.Arg93CyspathogenicKnownPCSK9Missensec.277C \> Tp.Arg93CyspathogenicKnownPCSK9Missensec.277C \> Tp.Arg93CyspathogenicKnownPCSK9Missensec.277C \> Tp.Arg93CyspathogenicKnownPCSK9Missensec.277C \> Tp.Arg93CyspathogenicKnownPCSK9Missensec.1792G \> Ap.Ala598Thrlikely pathogenicPutativePCSK9c.517C \> Tp.Pro173SerbenignPutativePCSK9c.1954A \> Gp.Asn652AspbenignPutativeAPOBMissensec.10579C \> Tp. Arg3527TrppathogenicKnownLDLRAP1Missensec.65G \> Cp.Trp22Serlikely pathogenicPutativeLDLRAP1Missensec.274G \> Ap.Val92Metlikely pathogenicPutative*LDLR* low-density lipoprotein receptor, *APOB* apolipoprotein B, *PCSK9* proprotein convertase subtilisin/kexin type 9, *LDLRAP1* low-density lipoprotein receptor adaptor protein 1

Pathogenic mutations in LDLR, APOB, PCSK9 and LDLRAP1 genes were found in 17 of the 225 subjects (7.6%), and all pathogenic mutations were loss of function (LOF) and heterozygous. However, these mutations also included 7 PCSK9 LOF mutations. In contrast to LOF mutations in LDLR, APOB and LDLRAP1, PCSK9 LOF mutations could increase hepatic LDLR expressions and reduce circulating levels of LDL. One patient carried LDLR(c.129G \> C), PCSK9(c.277C \> T) and LDLRAP1(c.274G \> A) mutations, and all other patients carried a single gene mutation. As shown in a previous study \[[@CR7]\], the prevalence of FH was 4.4% in PMI patients diagnosed by genetic testing.

Clinical phenotypes of PMI patients {#Sec12}
-----------------------------------

Among the 225 PMI patients, their age at MI onset was (46.64 ± 7.21) years old. In addition, the average age at MI onset in 56 non-PMI patients was (73.73 ± 6.97) years old.

Compared to non-PMI patients, the PMI patients had a higher level of LDL-C or body mass index (BMI), and were more likely to have a smoking history and a family history of premature CAD (Table [2](#Tab2){ref-type="table"}). The logistic regression analysis showed that the differentially expressed risk factors were independent predictive factors for patients with PMI (Table [3](#Tab3){ref-type="table"}). Although the genetic factor (a family history of premature CHD) was associated with PMI (OR = 2.840; 95% CI: 1.075--7.503; *P* = 0.035), its impact on PMI was relatively weak, because PMI might also be affected by BMI, smoking and other factors.Table 2Clinical phenotypes of patients with PMIPatients with PMI (*n* = 225)Non-PMI patients (*n* = 56)*P* valueMale, n(%)188 (83.6)45 (80.4)0.569BMI (kg/m^2^)26.71 ± 3.5124.58 ± 4.120.001Age of MI onset (years)46.64 ± 7.2173.73 ± 6.97\< 0.001Family history of PCHD, n (%)49 (21.8)5 (8.9)0.029eGFR (ml/min/1.73m^2^)96.72 (82.49, 104.27)78.45 (67.71, 89.32)\< 0.001LDL-C (mmol/L)3.63 (2.97, 4.35)3.29 (2.49, 3.86)0.005LVEF (%)60.93 ± 10.2560.67 ± 8.750.861Gensini score54 (34, 79)58.5 (45.5, 83.5)0.107Multivessel lesion, n(%)176 (78.2)48 (85.7)0.212Smoking, n (%)153 (68.0)27 (48.2)0.006Hyperlipemia, n (%)75 (33.3)15 (26.8)0.347Hypertension, n (%)116 (51.6)35 (62.5)0.142Diabetes, n (%)83 (36.9)14 (25.0)0.094*PMI* premature myocardial infarction, *BMI* body mass index, *PCHD* premature coronary heart disease, *eGFR* estimated glomerular filtration rate, *LDL-C* low-density lipoprotein cholesterol, *LVEF* left ventricular ejection fraction; All *P* values represented the comparisons between PMI patients and non-PMI patients. Comparisons between groups were performed with the student's t-test for continuous variables and Chi-square test for categorical variables. *P* \< 0.05 was considered statistically significantTable 3Logistic regression analysis of PMI patientsRisk factorsBOR95%CIPLDL-C (mmol/L)0.4041.4981.127--1.9910.005Family history of PCHD, n (%)1.0442.8401.075--7.5030.035BMI (kg/m^2^)0.1721.1881.079--1.307\< 0.001Smoking, n (%)0.7322.0801.128--3.8350.019*PMI* premature myocardial infarction, *LDL-C* low-density lipoprotein cholesterol, *PCHD* premature coronary heart disease, *BMI* body mass index

In this study, PMI patients were divided into 4 groups according to their age (Table [4](#Tab4){ref-type="table"}). The proportions of males and patients with a smoking history were both \> 50% in all age groups. However, with the increase in age, both the proportion of males and the proportion of patients with a smoking history decreased. Besides, patients younger than 30 years old had the highest level of LDL-C, highest Gensini scores and the highest incidence with a family history of PCHD.Table 4Age-related Characteristics of PMI patientsAge ≤ 30 (*n* = 9)30 ≤ age \< 40 (*n* = 34)40 ≤ age \< 50 (*n* = 105)50 ≤ age \< 60 (*n* = 77)Male, n(%)9 (100)34 (100)93 (88.6)52 (67.5)Age at MI onset (years)28.33 ± 1.5837.74 ± 3.0246.33 ± 2.9153.57 ± 2.21BMI (kg/m^2^)29.17 ± 4.5328.42 ± 3.9026.81 ± 3.6425.52 ± 2.44Family history of PCHD, n (%)5 (55.6)11 (32.4)17 (16.2)16 (20.8)Smoking, n (%)9 (100)27 (79.4)73 (69.5)44 (57.1)LDL-C (mmol/L)3.98 (3.87,5.42)3.67 (3.18,4.36)3.61 (2.79,4.34)3.65 (3.10, 4.40)LVEF (%)52.16 ± 11.9658.92 ± 10.2560.96 ± 10.5662.81 ± 9.04Gensini scores78 (38,90)55 (25.25,86.76)62 (56.35,68.15)53 (35,78)Multivessel lesion, n(%)6 (66.7)27 (79.4)84 (80)59 (76.6)*PMI* premature myocardial infarction, *BMI* body mass index, *PCHD* premature coronary heart disease, *LDL-C* low-density lipoprotein cholesterol, *LVEF* left ventricular ejection fraction

Clinical phenotypes of patients carrying mutations {#Sec13}
--------------------------------------------------

Patients carrying mutations in different genes or different mutations of the same gene showed different levels of LDL-C and CHD severity (Table [5](#Tab5){ref-type="table"}). The LDL-C level and Gensini scores were the highest in patients carrying LDLR mutations, followed by patients carrying APOB mutations (Fig. [1](#Fig1){ref-type="fig"}).Table 5Clinical phenotypes of LDLR, APOB, PCSK9 and LDLRAP1 gene mutationsCaseGeneFunctionExonSites of the MutationLDL-C (mmol/L)Gensini ScoresCase1LDLRMissense3c.241C \> T4.8640Case2LDLRMissense3c.292G \> A3.8948Case3LDLRMissense10c.1525A \> G8.0054Case4LDLRMissense11c.1691A \> G4.35128Case5LDLRMissense11c.1691A \> G7.25100Case6LDLRMissense13c.1867A \> T5.72104Case7LDLRMissense14c.2054C \> T7.7478Case8LDLRMissense14c.2054C \> T6.37157Case9APOBMissense26c.10579C \> T4.9357Case10PCSK9Missense2c.277C \> T3.2640Case11PCSK9Missense2c.277C \> T2.6840Case12PCSK9Missense2c.277C \> T1.66168Case13PCSK9Missense2c.277C \> T3.4612Case14PCSK9Missense2c.277C \> T3.0265Case15PCSK9Missense3c.1792G \> A3.60117Case16LDLRAP1Missense1c.65G \> C2.6654Case17LDLR+PCSK9+LDLRAP12.5062*LDLR* low-density lipoprotein receptor, *APOB* apolipoprotein B, *PCSK9* proprotein convertase subtilisin/kexin type 9, *LDLRAP1* low-density lipoprotein receptor adaptor protein 1Fig. 1LDL-C levels and Gensini scores of patients carrying mutations. LDLR, low-density lipoprotein receptor; APOB, apolipoprotein B; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLRAP1, low-density lipoprotein receptor adaptor protein 1

The LDL-C level of patients carrying PCSK9 LOF mutations ranged from 1.66 mmol/L to 3.60 mmol/L, but the level of LDL-C did not match the severity of CHD. For example, the LDL-C level in Case 12 was only 1.66 mmol/L, but the Gensini score of this patient was the highest among patients carrying PCSK9 LOF mutations (Table [5](#Tab5){ref-type="table"}). Most of these patients had a smoking history, and some of them suffered from diabetes and hypertension.

Clinical phenotypes of FH patients {#Sec14}
----------------------------------

Among the 225 PMI patients, 11 (4.9%) patients met at least two of the Chinese criteria for FH diagnosis. Of these patients, 2/11 (1.8%) patients were also diagnosed by genetic testing. At the end, a total of 19 patients (8.4%) were diagnosed as FH. The proportion of smoking subjects in FH patients was higher than that in non-FH patients (Table [6](#Tab6){ref-type="table"}).Table 6Clinical phenotypes of FH patientsFH patients (*n* = 19)Non-FH patients (*n* = 206)*P* valueMale, n(%)17 (89.5)171 (83.0)0.467BMI (kg/m^2^)27.82 ± 5.2826.60 ± 3.300.334Age at MI onset (years)46.68 ± 7.9750.43 ± 7.910.050Family history of PCHD, n (%)11 (57.9)38 (18.4)\< 0.001eGFR (ml/min/1.73m^2^)93.95 (76.40, 101.71)97.37 (84.17, 104.48)0.435LDL-C (mmol/L)4.93 (4.80, 6.37)3.58 (2.95, 4.21)\< 0.001LVEF (%)61.31 ± 12.2260.90 ± 10.080.869Gensini scores62 (48, 92)53.5 (32, 77.25)0.087Tendon xanthoma/corneal arcus n(%)0 (0)0 (0)1.000Multivessel lesion, n(%)15 (78.9)161 (78.2)0.936Smoking, n (%)17 (89.5)136 (66.0)0.036Hyperlipemia, n (%)11 (57.9)64 (31.1)0.018Hypertension, n (%)4 (21.1)112 (54.4)0.005Diabetes, n (%)7 (36.8)76 (36.9)0.996*FH* familial hypercholesterolemia, *LDL-C* low-density lipoprotein cholesterol, *BMI* body mass index, *LVEF* left ventricular ejection fraction. All *P* values represent comparisons between PMI patients and non-PMI patients. Comparisons between groups were performed with student's t-test for continuous variables and with Chi-square test for categorical variables. *P* \< 0.05 was considered statistically significant

Discussion {#Sec15}
==========

MI places a heavy psychological and the socioeconomic burden on "young" patients because it greatly affects the patients' ability to work,. The registration study of acute myocardial infarction in China (CAMI) showed that PMI patients accounted for about 27.7% of all MI patients \[[@CR11]\]. Because genetic factors play a great role in PMI, the identification of genetic variants conferring susceptibility to PMI is important for the prevention and management of this condition.

In this study, it was observed that 7.6% PMI patients carried FH-associated mutations and the value was higher than that reported in the study by Khera et al., who showed that a familial hypercholesterolemia mutation was present in 36 of 2081 (1.7%) patients with early-onset myocardial infarction \[[@CR12]\]. The above difference may be attributed to the different geographical regions and nationalities studied in the two reports \[[@CR13]\]. In this study, LDLR gene mutations made up the vast majority of all mutations. However, because all LDLRAP1 mutations are heterozygous, they are hence not pathogenic.

PCSK9 LOF mutations (PCSK9 c.277C \> T, c.1792G \> A) were also found in this study. In particular, as a mutation previously reported only in the Japanese population, the c.277C \> T mutation can decrease the level of LDL-C and reduce the risk of ASCVD \[[@CR14]\]. However, the patients in this study did not show lower levels of LDL-C and its reason might be their lifestyle and other environmental factors. In this study, the logistic regression analysis showed that smoking, obesity and family history of premature CHD were independent risk factors for PMI, suggesting that the lifestyle played an important role in the onset of PMI.

Men dominated PMI patients in most studies on PMI, including this study \[[@CR15], [@CR16]\], which may be attributed to the misperception that females are 'protective' against cardiovascular diseases. Previous studies have also shown that PMI patients were usually cigarette smokers and the proportion of PMI smokers increased over a decreasing age \[[@CR17], [@CR18]\], which was consistent with the result of this research. Since patients younger than 30 years were found to have more serious coronary artery lesions, both genetic (family history of PCHD) and environmental (smoking) factors play an important role in the onset of PMI.

The genotype-phenotype relationship of patients with FH-associated mutations showed high heterogeneity. Numerous studies have demonstrated that the carriers of LDLR mutations had the highest levels of LDL-C \[[@CR19], [@CR20]\], which was consist with the result of this research that showed the median LDL-C level in carriers of LDLR variants was 5.72 mmol/L and was higher than that in the carriers of other mutations. In addition, the coronary lesions in carriers of LDLR variants were more severe than those in carriers of other mutations. However, patients carrying the same mutation also showed obviously different levels of LDL-C and CAD severity. Such clinical heterogeneity might be attributed to the following reasons. On the one hand, the penetrance of these genes was not 100%; on the other hand, the different diets and lifestyles adopted by different patients might affect their clinical phenotypes.

In this study, the "2018 Chinese expert consensus of FH screening and diagnosis" was used first to diagnose FH. Only 2/11(1.8%) patients with clinical FH carried FH-associated gene mutations and the percentage was lower than that reported in a previous study, suggesting that different diagnostic criteria of FH may lead to different prevalence values of FH. Most studies have also found that 20--60% of subjects with phenotypic FH did not carry a causative mutation in LDLR, APOB, PCSK9 or LDLRAP1 genes, suggesting that phenotypic FH may also be induced by multiple small-effect common variants, mutations in unknown FH-associated genes, or environmental factors \[[@CR21], [@CR22]\]. None of the FH patients in this study had Tendon xanthoma/corneal arcus, which was consistent with the results of previous studies \[[@CR23], [@CR24]\].

Nevertheless, several limitations in this study need to be addressed. Firstly, the sample size in this study is small and may cause a statistical bias. Secondly, the approach used in this study to annotate missense variants by prediction algorithms may lead to misclassification in some cases, and the predicted variants need to be validated through in vitro functional experiments. Thirdly, only 4 FH-associated common genes were detected in this study, while some other rare FH-associated genes, including APOE and STAP1, were not detected.

In conclusion, FH-associated gene mutations were present in about 7.6% of Chinese PMI patients. In addition to genetic factors, smoking history, lifestyle and other environmental factors may play a synergistic role in determining the phenotype of PMI.
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